7.1 Prospective Drug Utilization Review (DUR) Standards

7.1 Prospective Drug Utilization Review (DUR) Standards

Prospective Drug Utilization Review (DUR) represents the pharmacist's primary clinical gatekeeping function in modern medication dispensing. Far from a perfunctory software verification or administrative check, prospective DUR is an individualized, patient-specific clinical evaluation mandated by both federal statute and Commonwealth of Virginia administrative law. The objective of prospective DUR is to identify, prevent, and resolve potential drug therapy problems before a single medication dose leaves the pharmacy.

On the Virginia MPJE, candidates must demonstrate complete mastery of the statutory origins of prospective DUR, the distinct categories of drug therapy problems that must be screened, the mandatory components of patient medication profiles, the exclusive clinical authority of the licensed pharmacist, and the rigorous documentation required when high-severity clinical alerts are overridden.

---

Statutory and Regulatory Foundations: OBRA '90 to Virginia Law

The statutory mandate for prospective DUR originated at the federal level within the Omnibus Budget Reconciliation Act of 1990 (OBRA '90), codified at 42 U.S.C. § 1396r-8(g). Congress initially established DUR requirements as a condition for state participation in the federal-state Medicaid program, aiming to improve clinical outcomes, reduce adverse drug events, and curb unnecessary pharmaceutical expenditures.

However, pharmacy practice standards and public safety cannot be stratified by payer status. The Commonwealth of Virginia, through the Virginia General Assembly and the Virginia Board of Pharmacy, promulgated regulations that expand prospective DUR obligations to all patients and all prescriptions, regardless of whether the payer is Virginia Medicaid, commercial insurance, Medicare Part D, or an uninsured cash-paying patient. In Virginia, prospective DUR is codified in the Virginia Board of Pharmacy Regulations at 18 VAC 110-20-270 (acts restricted to licensed pharmacists) and 18 VAC 110-20-276 (prospective drug review and patient records).

Evolution and Taxonomy of Drug Utilization Review (DUR):
├── Prospective DUR (Point-of-Care Dispensing): Evaluates therapy BEFORE medication is dispensed (18 VAC 110-20-276)
├── Concurrent DUR (Inpatient / Institutional): Real-time continuous monitoring during ongoing patient therapy
└── Retrospective DUR (Post-Dispensing Committee Review): Aggregate population-level data analysis by state Medicaid boards

While retrospective DUR involves periodic, computerized reviews of claims data by state committees to identify historical prescribing patterns, fraud, and population trends, prospective DUR is an immediate point-of-care clinical evaluation conducted by the dispensing pharmacist at the exact time a prescription or refill is presented.

---

The Seven Mandatory Screening Criteria (18 VAC 110-20-276)

Under 18 VAC 110-20-276(A), prior to dispensing each new prescription or authorized refill, a pharmacist must examine the patient's prescription record and profile to identify potential drug therapy problems. The regulation specifies seven distinct screening parameters that must be evaluated:

1. Over-Utilization or Under-Utilization

• Over-Utilization: The patient is obtaining refills too frequently, signaling medication hoarding, diversion into illicit channels, dose escalation without medical authorization, or miscomprehension of dosing directions. Over-utilization is a primary clinical indicator of controlled substance abuse and adverse toxicity.
• Under-Utilization: The patient is filling chronic maintenance medications late (e.g., antiepileptic agents, anticoagulants, antihypertensives, or antiretrovirals). Under-utilization indicates therapeutic non-adherence, which can lead to disease progression, treatment failure, acute hospitalizations, and fatal complications.

2. Therapeutic Duplication

• The concurrent prescribing or dispensing of two or more medications from the exact same chemical or therapeutic class, or medications possessing identical mechanisms of action, without a documented clinical rationale.
• Clinical Examples: A patient receiving concurrent prescriptions for lisinopril and losartan (dual renin-angiotensin-aldosterone system blockade without proven clinical benefit and with heightened hyperkalemia and acute kidney injury risk), or concurrent therapy with two full-dose selective serotonin reuptake inhibitors (sertraline and escitalopram, precipitating life-threatening serotonin syndrome).

3. Drug-Disease Contraindications

• Circumstances where a prescribed medication is known to exacerbate, destabilize, or induce adverse outcomes in a patient's documented underlying medical condition.
• Clinical Examples: Prescribing a non-cardioselective beta-blocker (e.g., propranolol) to a patient with documented severe asthma or chronic obstructive pulmonary disease (COPD), provoking acute bronchospasm; or dispensing systemic nonsteroidal anti-inflammatory drugs (NSAIDs) to a patient with advanced chronic kidney disease (CKD stage 4/5) or active peptic ulcer disease.

4. Drug-Drug Interactions (Including OTC Medications)

• Adverse pharmacokinetic or pharmacodynamic interactions between two or more co-administered drugs. Virginia law explicitly mandates that this review include interactions with non-prescription (over-the-counter) medications and herbal dietary supplements listed on the patient profile.
• Clinical Examples: Co-administration of ciprofloxacin (a potent CYP1A2 inhibitor) with theophylline, causing severe theophylline toxicity and seizures; dispensing simvastatin 80 mg concurrently with amiodarone (increasing rhabdomyolysis risk); or an OTC non-steroidal anti-inflammatory drug (ibuprofen) taken by a patient maintained on chronic warfarin therapy, drastically elevating gastrointestinal hemorrhage risk.

5. Incorrect Drug Dosage or Duration of Treatment

• Doses falling outside recognized therapeutic ranges (either supratherapeutic or subtherapeutic), or courses of therapy extending beyond established safety parameters.
• Clinical Examples: Prescribing oral ketorolac beyond the strict 5-day maximum combined systemic therapy limit, risking acute renal failure and massive GI bleeding; geriatric patients prescribed excessive doses of benzodiazepines contrary to Beers Criteria; or pediatric amoxicillin prescribed at an adult fixed dose rather than weight-based milligram-per-kilogram parameters.

6. Drug-Allergy Interactions

• Administering a drug to a patient with a documented immunologic hypersensitivity or well-characterized cross-reactivity to that chemical class.
• Clinical Examples: Prescribing amoxicillin to a patient with a documented history of severe penicillin-induced anaphylaxis; or dispensing a sulfonamide antibiotic (sulfamethoxazole/trimethoprim) to a patient with documented Stevens-Johnson syndrome resulting from prior sulfa exposure.

7. Clinical Abuse or Misuse

• Recognizing patterns indicative of psychological dependence, substance use disorder, diversion, or non-medical use. This includes multiple prescribers issuing identical controlled substance classes, rapid dose escalations, altered prescription blanks, or early refill requests alleging lost or destroyed medication.

---

Mandatory Patient Medication Profiles (18 VAC 110-20-276)

A prospective DUR cannot be executed in a clinical vacuum; it requires an accurate, comprehensive patient history. Under 18 VAC 110-20-276(B), a pharmacy must make reasonable efforts to obtain, record, and maintain a patient profile for every individual for whom a prescription is dispensed. The profile must be maintained in an immediately retrievable format (electronic pharmacy database or paper record system) and must contain:

1. Patient Demographic Identifiers: Full legal name, residential address, telephone number, date of birth (or age), and gender.
2. Clinical Patient History: Known chronic medical conditions, documented disease states, and significant physical impairments.
3. Known Allergies and Sensitivities: Complete record of drug allergies, adverse drug reactions, and idiosyncrasies (or an affirmative notation that the patient has "no known drug allergies" [NKDA]).
4. Comprehensive Medication History: A complete list of all prescription medications, devices, and relevant non-prescription (OTC) medications and supplements dispensed by or reported to the pharmacy.
5. Pharmacist Clinical Notes: Professional impressions, documented prescriber consultations, allergy clarifications, and rationales for therapeutic overrides.

Exam Tip: If a patient or caregiver refuses or is unable to provide allergy, disease, or medical history information, the pharmacist is not legally barred from dispensing. However, the pharmacist must document the patient's refusal or inability to provide the data in the pharmacy record to satisfy regulatory compliance.

---

Exclusive Pharmacist Clinical Authority vs. Automated Systems

A central principle of Virginia pharmacy jurisprudence is that prospective DUR is a clinical cognitive function exclusively restricted to licensed pharmacists and registered pharmacy interns acting under the direct, personal supervision of a pharmacist (18 VAC 110-20-270).

Non-Delegable Clinical Duty

• Pharmacy Technicians STRICTLY PROHIBITED: Under Virginia law, registered pharmacy technicians and pharmacy technician trainees cannot perform prospective DUR. Technicians may input demographic data, scan prescription blanks, and count tablets, but they are legally barred from interpreting clinical screening results, evaluating drug interactions, assessing organ dosing, or clearing clinical alerts.
• Intern Clinical Boundaries: A registered pharmacy intern may perform prospective DUR, but every intern evaluation and recommendation remains under the direct supervision and legal responsibility of the supervising preceptor pharmacist.

Software Alerts Are Not Clinical Substitutes

In modern community and institutional dispensing, pharmacy management systems automatically flag potential drug interactions, duplicate therapies, and dose anomalies using commercial clinical decision support (CDS) algorithms. The Virginia Board of Pharmacy makes it unequivocally clear: computerized alert systems are technical screening aids, not a legal substitute for professional pharmacist review.

• The software merely flags a theoretical risk based on pre-programmed parameters.
• The licensed pharmacist must apply individualized clinical judgment, evaluating patient-specific variables such as serum creatinine, estimated creatinine clearance, liver enzymes, chronological age, clinical indication, dosing schedules, and duration of therapy.

The Legal and Regulatory Perils of "Alert Fatigue"

In high-volume dispensing environments, pharmacists are inundated with hundreds of automated pop-up warnings daily, leading to alert fatigue—the sensory overload that causes clinicians to reflexively bypass or click through warnings without reading them.

In administrative disciplinary proceedings before the Virginia Board of Pharmacy and civil medical malpractice litigation, alert fatigue is never an acceptable legal defense. If a dispensing system flags a severe drug interaction (e.g., methadone and fluconazole producing QTc prolongation and fatal Torsades de Pointes) and the pharmacist overrides the alert without evaluating the patient's record, consulting the prescriber, or documenting clinical justification, the Board treats the conduct as gross negligence and unprofessional conduct under Va. Code § 54.1-3316.

---

Clinical Overrides and Mandatory Intervention Documentation

When a prospective DUR reveals a potential drug therapy problem, the pharmacist must take appropriate clinical action calibrated to the severity of the identified risk. Clinical alerts generally fall into three operational tiers:

Clinical Alert Severity Hierarchy:
├── Tier 1: Severe / Absolute Contraindication ──► STOP DISPENSING: Mandatory prescriber contact & clinical resolution
├── Tier 2: Major / Clinically Significant ──────► Evaluate patient profile, lab values, organ function; consult if needed
└── Tier 3: Moderate / Minor Informational ──────► Clinical review, patient counseling point, monitor ongoing therapy

Operational Override Protocol for High-Severity Alerts

When a Tier 1 (contraindicated) or high-severity Tier 2 alert is triggered, the pharmacist must execute the following standardized clinical protocol before dispensing:

1. In-Depth Profile Review: Examine active and historical medications, dispensing dates, prescriber specialties, and documented clinical diagnoses.
2. Patient Clinical Assessment: Inquire with the patient or caregiver regarding their current dosing schedule, previous tolerance of the medication combination, recent laboratory monitoring (e.g., INR, potassium, serum creatinine), and symptoms of adverse effects.
3. Prescriber Consultation: Contact the prescribing practitioner directly when an unresolved contraindication, major dosing error, or severe interaction exists. Discuss therapeutic alternatives, dose reductions, or staggered administration schedules.
4. Mandatory Clinical Documentation: If the prescriber instructs the pharmacist to dispense the medication despite the alert, or if the pharmacist determines through clinical evidence that the combination is clinically appropriate under close monitoring, the pharmacist must create an immediate, permanent clinical note in the pharmacy record (electronic dispensing system or written on the prescription).

Required Documentation Elements

Under Virginia Board standards, a legally defensible override note must include:

• Date and exact time of the clinical evaluation;
• Specific clinical interaction or alert identified (e.g., "Severe hyperkalemia risk: spironolactone + lisinopril + potassium chloride");
• Full name and title of the prescriber or authorized agent consulted;
• Clinical rationale agreed upon (e.g., "Prescriber aware; patient admitted to home health with daily BMP checks; baseline K+ 4.1 mEq/L; instructed patient on signs of hyperkalemia"); and
• Unique identifier or signature of the reviewing pharmacist.

Simply clicking a generic drop-down reason such as "Prescriber Approved" or "Patient Tolerating" without factual clinical notes fails to satisfy the professional standard of care under Virginia law.